RESEARCH ARTICLE

Efficacy of immunonutritional supplement after neoadjuvant chemotherapy in patients with esophageal cancer

Chao Luo1, Kai Xie2, Chi Zhang3, Zhuang-Zhuang Cong3, Wen-Feng Gu3, Yang Xu2, Yong Qiang4, Xiao-Kun Li4, Chao Zheng4*, Li-Wen Hu3* and Yi Shen1,2,3,4*

Abstract

Background: In recent years, preoperative nutrition has received great attention, especially for patients who received surgical reconstruction of the digestive tract such as esophagectomy. Preoperative nutrition therapy was reported to accelerate the patient’s postoperative recovery. In addition, immune suppression, nausea, and vomiting may lead to poor immune and nutritional status of patients with esophageal cancer who underwent neoadjuvant chemotherapy (NAC), which is not conducive to surgery. Therefore, preoperative nutritional treatment is necessary for patients with esophageal cancer who underwent NAC.

Method: Patients with esophageal cancer who received NAC at Nanjing Jinling Hospital from January 2018 to September 2020 were retrospectively identified. Patients were divided into enteral immunonutrition (EIN) group (those who received a conventional diet and immunonutrition supplement, Peptisorb, Nutricia, 500 mL/day * 7 via oral intake), and control group (those who only received a conventional diet were divided into). The primary outcomes were immune and nutritional indicators changes, including immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin G (IgG), and albumin (ALB), which were measured at preoperative day (PRD) 7, PRD-1, postoperative day (POD) 1 and POD-7. The secondary outcomes were postoperative complications, adverse reactions, and length of hospital stay.

Results: A total of 124 eligible patients were included in the study, with 21 patients in EIN group. After 1:2 matching, significant difference in baseline characteristics between the two groups was not observed (EIN: n = 21, Control group: n = 42). Compared with the control group, the IgA is significantly increased in the EIN group at POD-7 (p = 0.017). However, we observed that the IgM level in the control group was significantly higher than those in the EIN group at POD-7 (p = 0.007). The incidence of pneumonia and total complications in the EIN group were significantly lower than those in control group (p = 0.024, p = 0.028, respectively). There is no significant difference in ALB and adverse reactions between two groups (p = 0.303, p = 0.108, respectively).

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Esophageal cancer is one of the most common tumors and ranks sixth in mortality worldwide [1]. NAC combined with surgery is one of the common treatments for patients with locally advanced esophageal cancer [2]. For these patients, NAC may significantly enable them to obtain a better overall survival rate [3]. However, NAC may lead to a delay in surgery and an amplification of operative and postoperative complications [3, 4]. Dysphagia and weight loss in patients with esophageal cancer will lead to malnutrition. Nausea and vomiting often occur during the period of NAC, which will aggravate malnutrition of patients and is not conducive to the follow-up treatment of patients. It is reported that preoperative malnutrition will also affect the postoperative prognosis, including complications and adverse reactions [5, 6]. The interval between NAC and surgery provides the possibility to correct the deterioration of nutritional status before esophagectomy [7]. Immune-modulating substances such as arginine, omega-3 fatty acids, and antioxidants can modulate immune and inflammatory processes in major surgery and improve clinical outcomes. Arginine is a non-essential amino acid that plays a role in the synthesis of nitric oxide, which regulates gene expression and stimulates cell-mediated immunity [8].

However, there are few studies to explore the effect of immunonutrition therapy/supplement after NAC in patients with esophageal cancer. So, we conducted a retrospective study to explore the effects of preoperative immunonutritional support after NAC on postoperative immunonutritional parameters, postoperative complication, adverse reaction, and length of hospital stay in patients with esophageal cancer.

Materials and methods
Patients
Between 2018.01 and 2020.09, 1168 was diagnosed with esophageal cancer in Jinling hospital (Fig. 1). 1001 patients who didn’t receive neoadjuvant chemotherapy were excluded. Twenty-eight patients were withdrawn without esophagectomy. Of the remained 139 patients underwent esophagectomy, 15 patients were excluded due to allergic to soy or milk, unable to swallow, or individual data missing > 5%. Finally, 124 patients were eligible for the study. 103 patients in the control group and 21 patients in the EIN group were analyzed. A propensity score matching analysis was performed to reduce the effects of characteristics. Finally, 42 patients were included in the control group and 21 patients were included in the EIN group.

Study design
A retrospective study was performed between January 1, 2018, and September 1, 2020, at the Department of Cardiothoracic Surgery, Jinling Hospital, Nanjing, China. All patients included in the study received two courses of NAC. The chemotherapy regimen was paclitaxel plus cisplatin. Patients in the EIN group received enteral immune nutrition fluids (500 mL/day, Enteral Nutritional Emulsion, ω-3 Fatty Acids, Arginine) with their regular meals consecutively for a week after NAC, and the control group received only regular meals consecutively for a week after NAC. The primary endpoints were immune and nutritional parameters, including IgM, IgA, IgG, and ALB, which were measured at PRD-7, PRD-1, POD-1, and POD-7. The secondary endpoints were complications, adverse reactions, and length of hospital stay. Postoperative complications included anastomotic fistula, pneumonia, chylothorax, and recurrent laryngeal nerve injury. All postoperative complications were evaluated according to Clavien-Dindo criteria and grade II or more was defined as positive [9].

Meanwhile, baseline characteristics of all included patients were extracted from the hospital information system (HIS), including age, sex, body mass index (BMI), comorbidities, TNM stage, tumor site, differentiation grade, size. Tumor staging was based on the seventh edition of the International Union for Cancer Control (UICC) TNM staging system for esophageal carcinoma.

Objects of study
The inclusion criteria were as follows: (1) Patients who received NAC (2) Patients who underwent esophagectomy. Patients were excluded when: (1) Patients without esophagectomy due to: (1) Refusal; (2) Without pathologic response; (3) Severe toxic effects of chemotherapy; (2) Patients excluded due to: (1) Allergic to soy or milk; (2) Unable to swallow; (3) Individual data missing > 5%.

Statistical analyses
Continuous variables were performed as the mean with standard deviation (SD) or median with interquartile

Conclusion:
Immunonutritional supplement after NAC is an effective strategy to improve the postoperative immune status of esophageal cancer patients and could reduce the incidence of infectious complication. More well-designed prospective studies are needed to verify and update our finding.

Keywords: Esophageal cancer, Neoadjuvant chemotherapy, Immunonutrition, Nutritional status
ranges (IQR). The student t-test, χ² tests or Fisher’s exact tests were utilized to compare the difference between the two groups. We created a propensity score matched cohort by attempting to match each patient receiving enteral immune nutrition fluids with their regular meals with a patient receiving regular meals (1:2 match). The covariates included in the propensity score matching were age, sex, BMI, diabetes, hypertension, smoking, and alcohol. All statistical analyses were executed with Stata 16.0 (Stata Corp LLC, college station, USA). P < 0.05 was considered statistically significant.

Results
As showed in Fig. 1, a total of 1168 patients were screened and 1001 patients who didn’t receive neoadjuvant chemotherapy were excluded. Twenty-eight patients were withdrawn without esophagectomy. Of the remained 139 patients underwent esophagectomy, 15 patients were excluded due to allergic to soy or milk, unable to swallow, or individual data missing >5%. Finally, 124 patients were eligible for the study. 103 patients in the control group and 21 patients in the EIN group were analyzed. After a propensity score matching, 42 patients were included.


| Characteristics                  | Before matching |       | p value | After matching |       | p value |
|----------------------------------|-----------------|-------|---------|----------------|-------|---------|
|                                  | Control group (n = 103) | EIN group (n = 21) |         | Control group (n = 42) | EIN group (n = 21) |         |
| Age (years)                      | 63.58 ± 7.2     | 61.95 ± 7.68 | 0.352   | 61.02 ± 7.25 | 61.95 ± 7.68 | 0.649 |
| Sex                              |                 |       |         |                |       |         |
| Man                              | 87              | 18    | 0.885   | 33             | 18    | 0.496 |
| Female                           | 16              | 3     |         | 9              | 3     |         |
| BMI (kg/m²)                      | 23.48 ± 3.56    | 21.92 ± 3.50 | 0.068   | 21.7 ± 3.201  | 21.92 ± 3.50 | 0.855 |
| Diabetes                         |                 |       | 0.661   |                |       | 0.595 |
| Yes                              | 7               | 2     |         | 2              | 2     |         |
| No                               | 96              | 19    |         | 40             | 19    |         |
| Hypertension                     |                 |       | 0.179   | > 0.999        |       | > 0.999 |
| Yes                              | 35              | 4     |         | 9              | 4     |         |
| No                               | 68              | 17    |         | 33             | 17    |         |
| Smoking                          |                 |       | 0.417   | > 0.999        |       | > 0.999 |
| Yes                              | 59              | 10    |         | 20             | 10    |         |
| No                               | 44              | 11    |         | 22             | 11    |         |
| Alcohol                          |                 |       | 0.795   | > 0.999        |       | > 0.999 |
| Yes                              | 62              | 12    |         | 23             | 12    |         |
| No                               | 41              | 9     |         | 19             | 9     |         |
| Type of operation                |                 |       | 0.327   | > 0.999        |       | > 0.999 |
| Minimal invasive                 | 61              | 10    |         | 19             | 10    |         |
| Open                             | 42              | 11    |         | 23             | 11    |         |
| Operation time (h)               | 3.73 ± 0.83     | 4.03 ± 0.82 | 0.133   | 3.63 ± 0.749  | 4.03 ± 0.82 | 0.057 |
| T stage                          |                 |       | 0.650   | > 0.999        |       | > 0.999 |
| T1                               | 8               | 1     |         | 3              | 1     |         |
| T2                               | 17              | 5     |         | 6              | 5     |         |
| T3                               | 57              | 9     |         | 24             | 9     |         |
| T4                               | 5               | 2     |         | 3              | 2     |         |
| Unknown                          | 16              | 4     |         | 6              | 4     |         |
| N stage                          |                 |       | 0.917   | > 0.999        |       | > 0.999 |
| N0                               | 42              | 7     |         | 21             | 7     |         |
| N1                               | 30              | 7     |         | 11             | 7     |         |
| N2                               | 17              | 4     |         | 7              | 4     |         |
| N3                               | 3               | 0     |         | 0              | 0     |         |
| 4 (unknown)                      | 11              | 3     |         | 3              | 3     |         |
| M stage                          | 0               | 0     |         | 0              | 0     |         |
| Tumor site                       |                 |       | 0.555   | > 0.999        |       | > 0.999 |
| Upper                            | 8               | 1     |         | 3              | 1     |         |
| Middle                           | 63              | 11    |         | 30             | 11    |         |
| Lower                            | 32              | 9     |         | 9              | 9     |         |
| Degree of differentiation        |                 |       | 0.338   | > 0.999        |       | > 0.999 |
| Well                             | 13              | 5     |         | 8              | 5     |         |
| Moderately                       | 66              | 13    |         | 23             | 13    |         |
| Poorly                           | 24              | 3     |         | 11             | 3     |         |
| Size (cm)                        | 3.67 ± 1.63     | 3.83 ± 1.76 | 0.671   | 3.18 ± 1.48  | 3.83 ± 1.76 | 0.126 |

BMI, body mass index; EIN, enteral immunonutrition; Minimal invasive: video-assisted thoracic surgery and Da Vinci robot assisted surgery
in the control group and 21 patients were included in the EIN group.

The baseline characteristics of patients were presented in Table 1. Significant differences were not observed between the two groups after propensity score matching.

Immune and nutritional indicator of all patients were measured at the four timepoints mentioned above shown in Table 2. Immune indicators (IgA) in the two groups have significantly differences at POD-7 ($p = 0.017$). However, patients in the control group have a higher level of IgM at POD-7 ($p = 0.007$). Nutritional indicator (ALB) in two groups has no significant difference at POD-7.

The secondary outcomes are listed in Table 3. The incidence of pneumonia and total complications in the EIN group were significantly lower than those in control group ($p = 0.024$, $p = 0.028$, respectively). There were no

---

**Table 2** Comparison of immune and nutritional parameters

| Items | Before matching | After matching |
|-------|-----------------|----------------|
|       | Control group (n = 103) | EIN group (n = 21) | Control group (n = 42) | EIN group (n = 21) |
| IgM   |                        |                  |                        |                  |
| PRD-7 | $1.27 \pm 0.42$ | $1.26 \pm 0.42$ | $1.30 \pm 0.40$ | $1.26 \pm 0.42$ |
| PRD-1 | $1.29 \pm 0.50$ | $1.28 \pm 0.53$ | $1.27 \pm 0.50$ | $1.28 \pm 0.53$ |
| POD-1 | $1.03 \pm 0.32$ | $0.99 \pm 0.50$ | $1.05 \pm 0.37$ | $0.99 \pm 0.50$ |
| POD-7 | $1.5 \pm 0.35$  | $1.18 \pm 0.33$ | $1.43 \pm 0.33$ | $1.18 \pm 0.33$ |
| IgA   |                        |                  |                        |                  |
| PRD-7 | $2.21 \pm 0.55$ | $2.20 \pm 0.58$ | $2.21 \pm 0.55$ | $2.20 \pm 0.58$ |
| PRD-1 | $2.23 \pm 0.67$ | $2.65 \pm 0.72$ | $2.48 \pm 0.620$ | $2.65 \pm 0.72$ |
| POD-1 | $1.94 \pm 0.59$ | $1.93 \pm 0.62$ | $1.92 \pm 0.70$ | $1.93 \pm 0.62$ |
| POD-7 | $2.13 \pm 0.65$ | $2.44 \pm 0.65$ | $2.02 \pm 0.65$ | $2.44 \pm 0.65$ |
| IgG   |                        |                  |                        |                  |
| PRD-7 | $11.65 \pm 2.5$ | $11.28 \pm 2.53$ | $11.39 \pm 2.51$ | $11.28 \pm 2.53$ |
| PRD-1 | $12.23 \pm 2.08$ | $12.72 \pm 1.93$ | $12.31 \pm 1.98$ | $12.72 \pm 1.93$ |
| POD-1 | $10.48 \pm 1.89$ | $10.78 \pm 1.7$ | $10.53 \pm 1.77$ | $10.78 \pm 1.7$ |
| POD-7 | $11.02 \pm 1.81$ | $11.90 \pm 1.77$ | $11.43 \pm 1.76$ | $11.90 \pm 1.77$ |
| ALB   |                        |                  |                        |                  |
| PRD-7 | $34.75 \pm 3.99$ | $33.95 \pm 4.12$ | $35.67 \pm 4.52$ | $33.95 \pm 4.12$ |
| PRD-1 | $40.19 \pm 3.96$ | $39.99 \pm 4.64$ | $41.16 \pm 4.01$ | $39.99 \pm 4.64$ |
| POD-1 | $33.42 \pm 3.46$ | $33.55 \pm 3.33$ | $33.54 \pm 4.09$ | $33.55 \pm 3.33$ |
| POD-7 | $35.14 \pm 4.18$ | $35.11 \pm 3.60$ | $33.926 \pm 4.58$ | $35.11 \pm 3.60$ |

**Table 3** Comparison of surgical outcomes between two groups

| Variables | Before matching | After matching |
|-----------|-----------------|----------------|
|           | Control group (n = 103) | EIN group (n = 21) | Control group (n = 42) | EIN group (n = 21) |
| Complication |                          |                  |                        |                  |
| All       | $42 \pm 0.600$ | $4 \pm 0.000$ | $20 \pm 0.028$ | $4 \pm 0.028$ |
| Anastomotic fistula | $11 \pm 0.999$ | $2 \pm 0.000$ | $3 \pm 0.000$ | $2 \pm 0.000$ |
| Pneumonia | $26 \pm 0.043$ | $1 \pm 0.001$ | $13 \pm 0.024$ | $1 \pm 0.024$ |
| Others    | $5 \pm 0.099$  | $1 \pm 0.001$  | $4 \pm 0.657$  | $1 \pm 0.657$  |
| Hospital stays (day) | $15 (13–17) \pm 0.039$ | $13 (11–16) \pm 0.081$ | $15 (13–16) \pm 0.007$ | $13 (11–16) \pm 0.007$ |
| Adverse reactions | $26 \pm 0.280$ | $3 \pm 0.108$ | $14 \pm 0.024$ | $3 \pm 0.024$ |

EIN, enteral immunonutrition, IgM, immunoglobulin M, IgA, immunoglobulin A, IgG, immunoglobulin G, ALB, albumin. PRD, preoperative days. POD, postoperative days

EIN, enteral immunonutrition, Others, chylothorax and recurrent laryngeal nerve injury
significant differences in the hospital stays and the incidence of adverse reaction between two groups.

Linear regression of anastomotic leakage (AL) and nutritional indicators are showed in the Additional file 1: Table S1. Anastomotic leakage has statistical significance for ALB at POD-1 ($p=0.038$), which should be discarded. Because anastomotic leakage generally does not occur on the first day after operation. There was no statistical significance in the nutritional way for ALB at POD-1 and POD-7. And anastomotic leakage has no statistical significance for IgM, IgA, IgG at POD-7.

 Logistic regression of type of operation and complications are showed in the Additional file 1: Table S2. Type of operation has no statistical significance for anastomotic leakage and pneumonia.

**Discussion**

Esophageal cancer is a common gastrointestinal tumor in the world. There are many treatment options for advanced esophageal cancer, one of which is neoadjuvant chemotherapy (NAC) combined with esophagectomy. Multimodality treatment, which implies NAC in combination with surgery, has shown a better survival benefit than surgery alone [10–12]. Malnutrition is highly prevalent in patients with esophageal cancer. Due to the influence of tumor, patients with esophageal cancer often have symptoms such as dysphagia, vomiting, insufficient nutritional intake, fatigue, weight, and muscle loss. The adverse effects of NAC, such as immune suppression, nausea and vomiting, combined with the clinical symptoms of esophageal tumor itself, will adversely affect the follow-up treatment. It’s very important to integrate the early screening of malnutrition and appropriate nutritional support into the overall preoperative management of esophageal cancer patients [13–16]. According to previous studies, preoperative nutritional support can improve postoperative nutritional status and immune function [17, 18].

In our study, immunoglobulin for patients with EIN was found to outstrip those who are without EIN. IgA was significantly higher in the EIN group ($p=0.017$) at POD-7. IgM in the control group is significantly higher than the EIN group ($p=0.007$). Although there is fewer differences in IgG between two groups from POD-1 to POD-7, IgG is still better in the EIN group.

Immunoglobulin plays an important role in the humoral immune system. IgA is divided into serum type and secretory type; the secretory type is the main antibody in mucosal infection. Patients with esophageal cancer always suffer from eating disorders for a long time which might cause intestinal mucosal barrier dysfunction [19]. EIN may be beneficial to maintain the integrity of the structure and function of intestinal mucosal cells, and to protect the intestinal mucosal barrier [20]. IgM appears first in infection. In control group, the incidence of pneumonia is higher than the EIN group. The high incidence of pneumonia in the control group could result in the high level of IgM, compared with the EIN group. Thus, EIN may be beneficial for patients with esophageal cancer after NAC by enhancing their immune function and reducing the incidence of infectious complication and length of hospital stay. However, some researchers uphold that there are no significant differences in clinical outcomes (complications, hospital stay) between treatment and control group, that used immunonutrition before esophageal cancer surgery [21–25]. But Alfred Adiamah et al. [26] thought that preoperative immunonutrition could lead to an appreciable and significant reduction in postoperative infectious complications and a tendency for a shortened length of hospital stay. The conclusion is consistent with our result. But the systematic review and meta-analysis included most gastrointestinal cancers but few esophageal cancers.

**Limitation**

It is a retrospective single-center study that may be subject to selection bias. And this is a small-scale study which may lead to unstable results; therefore, we will continue to conduct further studies with larger samples in this area to prove significant differences between the two groups. We did not conduct Kaplan–Meier curves to compare the difference in long-term survival between groups.

**Conclusion**

Immunonutritional supplement after NAC is an effective strategy to improve the postoperative immune status of esophageal cancer patients and reduce the incidence of infectious complication and length of hospital stay. More well-designed prospective studies are needed to verify and update our finding.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13019-022-01786-x.

Additional file 1: Table S1. Linear regression of anastomotic leakage (AL) and nutritional indicators. Table S2. Logistic regression of type of operation and complications.

Authors’ contributions

CL made a major contribution to the design of the research and the manuscript writing; KX, Z-ZC, and CZ was responsible for collecting the data; CZ was responsible for performing the statistical analysis; all authors took part in the.
promotion of the results’ interpretation and critically reviewed the manuscript’s first draft. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81172032) and the Natural Science Foundation of Jiangsu Province (BK20181239).

Declarations

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical University, Guangzhou, China. 2 Department of Cardiothoracic Surgery, Jinling Hospital, School of Clinical Medicine, Nanjing Medical University, Nanjing, China. 3 Department of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China. 4 Department of Cardiothoracic Surgery, Jinling Hospital, School of Medicine, Southeast University, Nanjing, China.

Received: 9 September 2021   Accepted: 13 March 2022
Published online: 19 March 2022

References
1. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. Ann Thorac Surg. 2015;1(4):505–27.
2. Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. Lancet. 2019;390(10101):2383–96.
3. Babic B, Fuchs HF, Bruns CJ. Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer? Chirurg. 2020;91(5):379–83.
4. Luu TD, Gaur P, Force SD, et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thorac Surg. 2008;85(4):1217–23 (discussion 23–4).
5. Mora RJ. Malnutrition: organic and functional consequences. World J Surg. 1999;23(6):520–5.
6. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, et al. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck. 1997;19(5):419–25.
7. Steenhagen E. Preoperative nutritional optimization of esophageal cancer patients. J Thorac Dis. 2019;11(11):S1553–5.
8. Ma C, Tsai H, Su W, et al. Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): a prospective, randomized, double-blind study. J Postgrad Med. 2018;64(3):155–63.
9. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
10. Lordick F, Mariette C, Haustermans K, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl S):v50–7.
11. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(23):2074–84.
12. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotheraphy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(11):11–20.
13. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.
14. Low DE, Allum W, De Manzoni G, et al. Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS®) society recommendations. World J Surg. 2019;43(2):299–330.
15. Chen MJ, Wu IC, Chen YJ, et al. Nutrition therapy in esophageal cancer: consensus statement of the Gastroenterological Society of Taiwan. Dis Esophagus. 2018;31(8):doy016.
16. Yu Z, Li S, Liu D, et al. Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients. J Thorac Dis. 2018;10(2):1050–7.
17. Wang R, Cai H, Li Y, et al. Impact exerted by nutritional risk screening on clinical outcome of patients with esophageal cancer. Biomed Res Int. 2018;2018:7894084.
18. Kaneiko S, Takeda S, Iida M, et al. Efficacy of perioperative immunonutrition in esophageal cancer patients undergoing esophagectomy. Nutrition. 2019;59:96–102.
19. Li X, Cong Z, Wu W, et al. Efficacy of 4 wk of home enteral feeding supplementation after esophagectomy on immune function: a randomized controlled trial. Nutrition. 2020;71:110787.
20. Zou XP, Chen M, Wei W, et al. Effects of enteral immunonutrition on the maintenance of gut barrier function and immune function in pigs with severe acute pancreatitis. J Parenter Enteral Nutr. 2010;34(5):554–66.
21. Hallay J, Kovács G, Kiss Sz S, et al. Changes in the nutritional state and immune-serological parameters of esophagectomized patients fed jejunally with glutamine-poor and glutamine-rich nutrients. Hepatogastroenterology. 2002;49(48):1555–9.
22. Mudge LA, Watson DJ, Smithers BM, et al. Multicentre factorial randomized clinical trial of perioperative immunonutrition versus standard nutrition for patients undergoing surgical resection of oesophageal cancer. Br J Surg. 2018;105(10):1262–72.
23. Ryan AM, Reynolds JV, Healy L, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009;249(3):355–63.
24. Sakurai Y, Masui T, Yoshida I, et al. Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients. World J Surg. 2007;31(11):1250–7 (discussion 8–9).
25. Healy LA, Ryan A, Doyle SL, et al. Does prolonged enteral feeding with supplemental omega-3 fatty acids impact on recovery post-oesophagectomy: results of a randomized double-blind trial. Ann Surg. 2017;266(5):720–8.
26. Adiamah A, Skolepa P, Weimann A, et al. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg. 2019;270(2):247–56.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.